• AAPL 169.67
  • TSLA 157.17
  • AMZN 183.855
  • MSFT 415.77
  • INTC 36.33
  • EURUSD 1.0625
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. PHIO.NASDAQ

Phio Pharmaceuticals Corp (PHIO NASDAQ) stock market data APIs

$0.67 0(0%) as of April 15, 2024

Phio Pharmaceuticals Corp Financial Data Overview

0.6656
0.67
-
0.68
0.649
0.5-6.85
3 056 K
4 592 K
0
-0.85
1.418
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'PHIO',
Type: 'Common Stock',
Name: 'Phio Pharmaceuticals Corp',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG0024FKD97',
ISIN: NULL,
CUSIP: NULL,
CIK: '1533040',
EmployerIdNumber: '45-3215903',
FiscalYearEnd: 'December',
IPODate: '2012-05-10',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic Primary',
IsDelisted: false,
}

Phio Pharmaceuticals Corp Fundamental Data is available in our Financial Data APIs

  • Net Revenue 0
  • EBITDA -10 564 000
  • Earnings Per Share -5.2
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Phio Pharmaceuticals Corp Earnings via APIs

  • Latest Release 2024-03-20
  • EPS/Forecast -1.3

Get Phio Pharmaceuticals Corp End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Phio Pharmaceuticals Corp latest news via APIs

Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is desig...
  • EARNINGS RELEASES AND OPERATING RESULTS
  • IMMUNOONCOLOGY
  • NASDAQ:PHIO
  • PHIO
  • PHIO PHARMACEUTICALS CORP
  • RNAI

Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is desig...
  • IMMUNOONCOLOGY
  • INTASYL
  • NASDAQ:PHIO
  • PHIO
  • PHIO PHARMACEUTICALS CORP
  • PRODUCT / SERVICES ANNOUNCEMENT
  • RNAI
Do you have any questions?
support@eodhistoricaldata.com